m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05713
|
[1] | |||
m6A modification
LINC00426
LINC00426
METTL3
Methylation
: m6A sites
Direct
Enhancement
Non-coding RNA
LINC00426
miR-200a-3p
lncRNA miRNA circRNA
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Methyltransferase-like 3 (METTL3) | WRITER | |||
| m6A Target | Long intergenic non-protein coding RNA 426 (LINC00426) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | Long intergenic non-protein coding RNA 426 (LINC00426) | LncRNA | View Details | ||
| Regulated Target | hsa-miR-200a-3p | View Details | |||
| Crosstalk Relationship | m6A → ncRNA | Enhancement | |||
| Crosstalk Mechanism | m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA | ||||
| Crosstalk Summary | METTL3 is believed to enhance the expression of Long intergenic non-protein coding RNA 426 (LINC00426) through m6A methylation modification.The LINC00426/hsa-miR-200a-3p/ZEB1 axis plays a crucial role in regulating E-cadherin, N-cadherin and vimentin during EMT in CC.Overexpression of LINC00426 in CC cells caused resistance to Cisplatin and Bleomycin, but sensitivity to imatinib. | ||||
| Responsed Disease | Cervical cancer | ICD-11: 2C77 | |||
| Responsed Drug | Cisplatin | ||||
| Pathway Response | PI3K-Akt signaling pathway | hsa04151 | |||
| Cell Process | Cell proliferation | ||||
| Cell migration | |||||
| Cell invasion | |||||
In-vitro Model |
HeLa | Endocervical adenocarcinoma | Homo sapiens | CVCL_0030 | |
| C-33 A | Cervical squamous cell carcinoma | Homo sapiens | CVCL_1094 | ||
| SiHa | Cervical squamous cell carcinoma | Homo sapiens | CVCL_0032 | ||
| In-vivo Model | HeLa cells were stably transfected with LINC00426 overexpression lentivirus. Subsequently, for subcutaneously implanted tumor model, mice were randomly divided into two groups, and cells (1 × 107/100 μl) mixed with the same volume of matrix gel were injected subcutaneously into the right abdomen of mice. One month later the mice were executed and the tumors were stripped and weighed, measured for volume, and used for further analysis. For tumor metastasis assay, mice were randomly grouped, and 5 × 105/100 μl HeLa cells transfected with NC and LINC00426 overexpression lentivirus were intravenously injected into the tail vein of BALB/c nude mice which were sacrificed after 1 month. | ||||
: m6A sites